Want to see A full AI Analyst Report?
Top Page
Agilent
(NYSE:A)
Select Model
Select Model
Rating:78Outperform
Price Target:
$177.00
▲(14.36% Upside)
Action:Reiterated
Date:08/27/26
The score is driven primarily by strong financial quality (healthy margins and rising free cash flow) and a very positive earnings update with raised FY26 guidance and expected margin expansion. Technicals also support the outlook with clear uptrend signals (price above key moving averages and positive MACD). These positives are tempered by premium valuation (P/E ~30.5 with a low ~0.53% dividend yield) and financial watch-items including the recent gross-margin step-down and higher debt.
Positive Factors
Recurring Revenue and Switching Costs
Agilent’s instrument base creates recurring demand for consumables, services and software. Validated methods, compliance requirements and integrated workflows raise switching costs, supporting customer retention and more resilient revenue over the medium term.
Negative Factors
Gross-Margin Compression
The sharp decline in gross margin suggests mix, pricing or cost pressures that could be structural rather than temporary. Persistent compression would reduce operating leverage and limit the earnings benefit of continued revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue and Switching Costs
Agilent’s instrument base creates recurring demand for consumables, services and software. Validated methods, compliance requirements and integrated workflows raise switching costs, supporting customer retention and more resilient revenue over the medium term.
Read all positive factors
Agilent Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyAgilent (A) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$43.80B
Dividend Yield0.52%
Average Volume (3M)2.20M
Price to Earnings (P/E)31.0
Beta (1Y)0.91
Revenue Growth8.60%
EPS Growth19.07%
CountryUS
Employees18,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)5.09
Shares Outstanding282,431,950
10 Day Avg. Volume2,342,360
30 Day Avg. Volume2,199,263
Financial Highlights & Ratios
PEG Ratio9.44
Price to Book (P/B)6.14
Price to Sales (P/S)5.96
P/FCF Ratio35.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$170.44Price Target Upside10.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)6.06
Revenue Forecast (FY)$7.45B
Agilent Business Overview & Revenue Model
Company Description
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portf...
How the Company Makes Money
Agilent makes money primarily by selling laboratory solutions that combine capital equipment (instruments) with recurring purchases (consumables) and ongoing support (services and software). A significant portion of revenue comes from selling anal...
Agilent Earnings Call Summary
Earnings Call Date:Aug 26, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Nov 30, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.Positive Updates
Revenue Beat and Organic Growth
Reported Q3 revenue of $1.88B, core (organic constant currency) growth of 7.3% year-over-year, and reported growth of 8.1%. Revenue exceeded the high end of guidance by ~140 basis points.
Negative Updates
One-Time Tariff Refunds Inflated Q3 Results
Q3 benefited from ~$20M in tariff refunds (approx. $0.06 EPS benefit). Gross margin and operating margin included ~160 bps and ~110 bps net benefits respectively in reported results, representing a one-time boost not included in future guidance.
Read all updates
Q3-2026 Updates
Positive
Negative
Revenue Beat and Organic Growth
Reported Q3 revenue of $1.88B, core (organic constant currency) growth of 7.3% year-over-year, and reported growth of 8.1%. Revenue exceeded the high end of guidance by ~140 basis points.
Read all positive updates
Company Guidance
Agilent raised its FY26 outlook to reported revenue of $7.49–$7.51 billion (core/organic constant‑currency growth 5.8%–6.0%; currency a ~1.6% tailwind) and increased full‑year EPS to $6.18–$6.21 including roughly $0.06 (≈$20M) of Q3 tariff‑refund benefit (ex‑refund EPS $6.12–$6.15, ~10% y/y growth at the midpoint; including refunds ≈11% growth). Management now expects operating‑margin expansion ex‑refund of >100 basis points at the midpoint (>130 bps including Q3 refunds), a tax rate of 14.5%, other income of $31M, 283M diluted shares outstanding, operating cash flow of $1.6–$1.7B and ~ $450M of capex. Q4 guidance is revenue $1.98–$2.00B (core growth ~5.2%–6.2%; ~10 bps currency headwind), EPS $1.71–$1.74 (8%–9% growth), includes ~ $23M from Biocare and excludes any future tariff‑refund benefit. Segment and regional assumptions were raised (CAM to high single‑digits; AMG and LDG to mid‑ to high‑single‑digits; ACG mid‑single‑digit; China mid‑single‑digits; Asia ex‑China double‑digits; Europe low single‑digits; Americas mid‑ to high‑single‑digits), and the revised guide implies a two‑year stacked core acceleration to ~11% versus flat in 2025.Agilent Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
81
Very Positive
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.37B | 6.95B | 6.51B | 6.83B | 6.85B | 6.32B |
| Gross Profit | 3.96B | 3.64B | 3.54B | 3.46B | 3.72B | 3.41B |
| EBITDA | 1.97B | 1.83B | 1.87B | 1.70B | 1.91B | 1.76B |
| Net Income | 1.44B | 1.30B | 1.29B | 1.24B | 1.25B | 1.21B |
Balance Sheet | ||||||
| Total Assets | 13.97B | 12.73B | 11.85B | 10.76B | 10.53B | 10.71B |
| Cash, Cash Equivalents and Short-Term Investments | 1.76B | 1.79B | 1.33B | 1.59B | 1.05B | 1.57B |
| Total Debt | 3.95B | 3.35B | 3.57B | 2.73B | 2.77B | 2.73B |
| Total Liabilities | 6.60B | 5.99B | 5.95B | 4.92B | 5.23B | 5.32B |
| Stockholders Equity | 7.36B | 6.74B | 5.90B | 5.84B | 5.30B | 5.39B |
Cash Flow | ||||||
| Free Cash Flow | 1.44B | 1.15B | 1.37B | 1.47B | 1.02B | 1.30B |
| Operating Cash Flow | 1.61B | 1.56B | 1.75B | 1.77B | 1.31B | 1.49B |
| Investing Cash Flow | -1.29B | -394.00M | -1.26B | -310.00M | -338.00M | -749.00M |
| Financing Cash Flow | -95.00M | -715.00M | -752.00M | -930.00M | -1.37B | -696.00M |
Agilent Technical Analysis
Positive
154.77
Price Trends
138.94
Positive
129.58
Positive
131.02
Positive
Market Momentum
5.06
Negative
67.13
Neutral
55.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Positive. The current price of 154.77 is above the 20-day moving average (MA) of 147.98, above the 50-day MA of 138.94, and above the 200-day MA of 131.02, indicating a bullish trend. The MACD of 5.06 indicates Negative momentum. The RSI at 67.13 is Neutral, neither overbought nor oversold. The STOCH value of 55.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for A.
Agilent Risk Analysis
Agilent disclosed 35 risk factors in its most recent earnings report. Agilent reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Agilent Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $43.80B | 30.98 | 20.84% | 0.59% | 8.60% | 19.07% | |
76 Outperform | $234.31B | 33.87 | 13.35% | 0.32% | 7.23% | 7.47% | |
75 Outperform | $28.02B | 31.62 | -1199.91% | ― | 6.91% | 12.43% | |
72 Outperform | $151.40B | 38.19 | 7.66% | 0.75% | 4.56% | 19.34% | |
71 Outperform | $14.10B | 61.77 | 3.27% | 0.25% | 4.05% | -10.40% | |
61 Neutral | $40.69B | 104.79 | 1.88% | ― | 52.47% | -63.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
A
Agilent
157.69
33.72
27.21%
DHR
Danaher
215.68
11.89
5.84%
MTD
Mettler-Toledo
1,407.43
124.32
9.69%
RVTY
Revvity
129.71
40.73
45.77%
TMO
Thermo Fisher
630.70
142.74
29.25%
WAT
Waters
421.26
123.61
41.53%
Agilent Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Agilent Completes $600 Million Senior Notes Offering
Neutral
Jun 25, 2026
On June 25, 2026, Agilent Technologies closed a $600 million private offering of 4.900% senior unsecured notes due January 15, 2032, sold to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S. The notes, pr...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
Agilent Appoints New Chief Accounting Officer Amid Growth
Positive
May 27, 2026
On May 20, 2026, Agilent appointed Tim Downs as vice president and chief accounting officer, effective after the filing of its April 30, 2026 Form 10-Q, succeeding retiring principal accounting officer Rodney Gonsalves, who will stay on in a trans...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.